The company said last night, “In addition to today’s medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantive dataset.” The data is from Cardiff ‘s lead program in first-line RAS-mutated metastatic colorectal cancer. Shares of Cardiff Oncology (CRDF) are down 8%, or 30c, to $3.10 in premarket trading.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Confident Buy Rating for Cardiff Oncology Amid Strategic Developments and Promising Trial Prospects
- Cardiff Oncology Appoints New Chief Medical Officer
- Cardiff Oncology appoints Roger Sidhu as chief medical officer
- Cardiff Oncology’s Onvansertib: Anticipated Phase II Results and Market Potential Drive Buy Rating
- Cardiff Oncology ‘highly encouraged’ by onvansertib data presented at ASCO